Tirzepatide vs. Semaglutide vs. Retatrutide: a sourcing comparison
Side-by-side sourcing notes for Semaglutide, Tirzepatide, and Retatrutide: receptor class, documentation depth, analytical risk, lead time, and buyer-fit questions.
Published May 8, 2026 · 8 min read · By Vialdyne Regulatory Team
Semaglutide, Tirzepatide, and Retatrutide are the three GLP-1-family molecules most often compared by metabolic-research and pharmacy-procurement buyers. They are not interchangeable sourcing items. The buyer decision should compare receptor class, analytical complexity, release-packet depth, fill flexibility, regulatory posture, and destination-market requirements before price is negotiated.
How should buyers compare Semaglutide, Tirzepatide, and Retatrutide?
Compare Semaglutide, Tirzepatide, and Retatrutide by receptor class, documentation requirements, route-specific testing, analytical confirmation, lead time, and country pathway. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a GIP / GLP-1 dual agonist. Retatrutide is studied as a GIP / GLP-1 / glucagon tri-agonist. The sourcing conversation should stay documentation-first, not disease-claim-first.
At a glance
| Item | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Buyer intent | Established GLP-1 comparator | Dual-agonist metabolic research | Tri-agonist metabolic research |
| Receptor class | GLP-1 | GIP / GLP-1 | GIP / GLP-1 / glucagon |
| Typical sourcing risk | Counterfeit and documentation gaps | Higher cost and method sensitivity | Investigational supply, higher premium |
| First packet priority | COA, HPLC, MS, water, counter-ion | COA, HPLC, MS, water, counter-ion, stability | COA, HPLC, MS, sequence confidence, stability |
| Buyer question | Is the lot traceable and current? | Can the supplier support vial size and recurring fill? | Can the supplier defend identity and timeline? |
Chemistry and analytical posture
Semaglutide is the most familiar benchmark in the class, but familiarity does not remove qualification work. Buyers still need a batch-specific COA, HPLC purity trace, mass-spec identity report, water content, counter-ion result, storage guidance, and retest date.
Tirzepatide is a 39-amino-acid GIP / GLP-1 dual agonist. It is longer and more expensive to source than many shorter research peptides, so first-lot review should check not only purity but also fill accuracy, moisture, salt form, and consistency between quoted and shipped vial size.
Retatrutide is usually the most documentation-sensitive of the three because buyers are often evaluating investigational tri-agonist workflows. Request the exact lot's HPLC and MS data before accepting a delivery window. For first qualification, ask whether sequence-level evidence or orthogonal identity support is available.
Documentation checklist for all three
- Batch-specific COA with lot number, manufacture date, retest date, and signed release decision
- HPLC chromatogram with integration table and method notes
- MS identity report matched to theoretical molecular weight
- Water content, residual solvents, and counter-ion status
- Stability summary or available study for recurring inventory planning
- LAL endotoxin and microbial-limit testing if the buyer's route or pathway requires it
- Import, destination-market, and buyer-license context before quote stage
How to choose the right sourcing track
Use Semaglutide when the procurement goal is a known GLP-1 comparator and documentation traceability is the main risk. Use Tirzepatide when the buyer needs dual-agonist metabolic-research supply with broader fill planning. Use Retatrutide when the buyer is specifically evaluating tri-agonist research and can tolerate longer qualification and higher per-mg cost.
Vialdyne treats all three as documentation-first RFQs. Send the molecule, destination market, buyer type, vial size, and required tests. QA will confirm which release documents are available before pricing.
Talk to our regulatory team
Comparing GLP-1-family peptide suppliers?
Tell us which molecule, vial size, destination market, and documentation scope you need. QA will map the release packet before quote.
Frequently asked questions
- How do Semaglutide, Tirzepatide, and Retatrutide differ by receptor class?
- Semaglutide is a GLP-1 receptor agonist; Tirzepatide is a GIP / GLP-1 dual agonist; Retatrutide is studied as a GIP / GLP-1 / glucagon tri-agonist. They are not interchangeable sourcing items — the receptor class drives different analytical and documentation priorities, so the procurement conversation should stay documentation-first rather than disease-claim-first.
- Which GLP-1 peptide is most documentation-sensitive to source?
- Retatrutide is usually the most documentation-sensitive of the three, because buyers are often evaluating investigational tri-agonist workflows. Request the exact lot's HPLC and MS data before accepting a delivery window, and ask whether sequence-level or orthogonal identity evidence is available for first qualification. Tirzepatide adds fill-accuracy and salt-form checks; Semaglutide's main risk is counterfeit and documentation gaps.
- What documentation should a buyer request for any GLP-1-family API?
- For all three: a batch-specific COA (lot number, manufacture date, retest date, signed release), an HPLC chromatogram with integration table and method notes, an MS identity report matched to theoretical molecular weight, water content / residual solvents / counter-ion status, a stability summary for recurring inventory, LAL endotoxin and microbial limits if the route requires them, and import / destination-market context before quote stage.